Axel Hauschild

10PUBLICATIONS
86CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersPattern recognitionHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 24, 2026
Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis.

|Aug 11, 2026
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

|Sep 04, 2023
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.

Alexander Cj van Akkooi, Axel Hauschild, Georgina V Long

|Apr 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany.

Peter Mohr, Emilie Scherrer, Chalid Assaf

|Jul 13, 2021
Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review.

Julia Höhn, Achim Hekler, Eva Krieghoff-Henning

|May 01, 2021
Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS.

R Gutzmer, H-J Schulze, A Hauschild

Pageof 2

Frequent Collaborators

5 joint publications

Friedegund Meier

4 joint publications

Jochen Utikal

4 joint publications

Sebastian Haferkamp

4 joint publications

Michael Weichenthal